Influence of piperacillin-tazobactam on pharmacokinetics of gentamicin given once daily

American Journal of Health-System Pharmacy

Volumn 54, Issue 23, 1997, Pages 2704-2708

  Hitt, Catherine M ^a   Patel, Kalpana B ^b   Nicolau, David P ^c   Zhu, Zhu ^c   Nightingale, Charles H ^c  

^a MAYO CLINIC   (United States)

^b Arnold and Marie Schwartz College of Pharmacy   (United States)

^c HARTFORD HOSPITAL   (United States)

Author keywords

Aminoglycosides; Blood levels; Dosage; Dosage schedules; Drug Interactions; Gentamicin; Halt life; Injections; Penicillins; Pharmacokinetics; Piperacillin sodium; Tazobactam sodium; lactamase inhibitors

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; BETA LACTAMASE INHIBITOR; GENTAMICIN; PENICILLIN DERIVATIVE; PIPERACILLIN PLUS TAZOBACTAM;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG INFUSION; DRUG METABOLISM; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0030782745     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/54.23.2704     Document Type: Article

References (26)

1. Higashitani F, Hyodo A, Ishida N et al. Inhibition of betalactamases by tazobactam and in-vitro antibacterial activity of tazobactam combined with piperacillin. J Antimicrob Chemother. 1990; 25:567-74.
2. Pass PJ, Prior RB. Comparative in vitro activities of piperacillin-tazobactam and ticarcillin-clavulanate. Antimicrob Agents Chemother. 1989; 33:1268-74.
3. Mehtar S, Drabu YJ, Blakemore PH. The in-vitro activity of piperacillin/tazobactam, ciprofloxacin, ceftazidime and imipenem against multiple resistant gram-negative bacteria. J Antimicrob Chemother. 1990; 25:915-9.
4. Nicolau DP, Freedman CD, Belliveau PP et al. Experience with a once-daily aminoglycoside program administered in 2,184 adult patients. Antimicrob Agents Chemother. 1995; 39:650-5.
5. Riff LJ, Jackson GG. Laboratory and clinical conditions for gentamicin inactivation by carbenicillin. Arch Intern Med. 1972; 130:887-91.
6. Pickering LK, Gearhart P. Effect of time and concentration upon interaction between gentamicin, tobramycin, netilmicin, or amikacin and carbenicillin or ticarcillin. Antimicrob Agents Chemother. 1979; 15:592-6.
7. Pickering LK, Rutherford I. Effects of concentration and time upon inactivation of tobramycin, gentamicin, netilmicin and amikacin by azlocillin, carbenicillin, mecillinam, mezlocillin and piperacillin. J Pharmacol Exp Ther. 1981; 217:345-9.
8. Glew RH, Pavuk RA. Stability of gentamicin, tobramycin, and amikacin in combination with four beta-lactam antibiotics. Antimicrob Agents Chemother. 1983; 24:474-7.
9. Fuchs PC, Stickel S, Anderson PH et al. In vitro inactivation of aminoglycosides by sulbactam, other beta-lactams, and sulbactam-beta-lactam combinations. Antimicrob Agents Chemother, 1991; 35:182-4.
10. Russo ME. Penicillin-aminoglycoside inactivation: another possible mechanism of interaction. Am J Hosp Pharm. 1980; 37:702-4.
11. Thompson MIB, Russo ME, Saxon BJ et al. Gentamicin inactivation by piperacillin or carbenicillin in patients with end-stage renal disease. Antimicrob Agents Chemother. 1982; 21:268-73.
12. Halstenson CE, Hirata CAI, Heim-Duthoy KL et al. Effect of concomitant administration of piperacillin on the dispositions of netilmicin and tobramycin in patients with end-stage renal disease. Antimicrob Agents Chemother. 1990; 34:128-33.
13. Chow MSS, Quintiliani R, Nightingale CH. In vivo inactivation of tobramycin by ticarcillin: a case report. JAMA. 1982; 247:658-9.
14. Uber WA, Brundage RC, White RL et al. In vivo inactivation of tobramycin by piperacillin. DICP Ann Pharmacother. 1991; 25:357-9.
15. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976; 16:31-41.
16. O'Leary TD, Ratcliff RM, Geary TD. Evaluation of an enzyme immunoassay for serum gentamicin. Antimicrob Agents Chemother. 1980; 17:776-8.
17. Klepser ME, Patel KB, Nicolau DP et al. Comparison of the bactericidal activities of ofloxacin and ciprofloxacin alone and in combination with ceftazidime and piperacillin against clinical strains of Pseudomonas aeruginosa. Antimicrob Agents Chemother, 1995; 39:2503-10.
18. Belliveau PP, Nicolau DP, Nightingale CH et al. Once-daily gentamicin: experience in one hundred eighteen patients with postpartum endometritis. J Infect Dis Pharmacother. 1995; 1:11-8.
19. Davis BD. Mechanism of the bactericidal action of the aminoglycosides. Microbiol Rev. 1987; 51:341-50.
20. Ebert SC, Craig WA. Pharmacodynamic properties of antibiotic: application to drug monitoring and dosage regimen design. Infect Control Hosp Epidemiol. 1990; 11:319-26.
21. Moore RD, Lietman PS, Smith CR. Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. J Infect Dis. 1987; 155:93-9.
22. Pieper JA, Vidal RA, Schentag JJ. Animal model distinguishing in vitro from in vivo carbenicillin-aminoglycoside interactions. Antimicrob Agents Chemother. 1980; 18:604-9.
23. Lathia C, Sia L, Lane R et al. Pharmacokinetics of piperacillin/tazobactam (pip/taz) IV with and without tobramycin IV in healthy adult male volunteers. Pharm Res. 1991; 8:5303. Abstract.
24. Sörgel F, Kinzig M. The chemistry, pharmacokinetics and tissue distribution of piperacillin/tazobactam. J Antimicrob Chemother. 1993; 31(suppl A):39-60.
25. Waitz JA, Drube CG, Moss EL et al. Biological aspects of the interaction between gentamicin and carbenicillin. J Antibiot (Tokyo). 1972; 25:219-25.
26. Shwed JA, Ceresia ML, Taylor AJ et al. Lack of effect of clavulanic acid on aminoglycoside inactivation by ticarcillin. J Infect Dis Pharmacother. 1995; 1:35-43.